WO2025067290 - PYRIMIDOPYRAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2025/067290
Publication Date
03.04.2025
International Application No.
PCT/CN2024/121282
International Filing Date
26.09.2024
Title **
[English]
PYRIMIDOPYRAZOLE COMPOUND, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
[French]
COMPOSÉ DE PYRIMIDOPYRAZOLE, COMPOSITION PHARMACEUTIQUE DE CELUI-CI ET UTILISATION ASSOCIÉES
[Chinese]
嘧啶并吡唑类化合物、其药物组合物及其用途
Applicants **
SUNSHINE LAKE PHARMA CO., LTD.
Inventors
XIE, Hongming
HUANG, Enhuo
FANG, Qinghong
ZHANG, Yingjun
Priority Data
202311261714.3
27.09.2023
CN
202410541353.6
30.04.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3320 | |
| EPO | Filing, Examination, Granting | 19613 | |
| Japan | Filing, Examination, Granting | 2309 | |
| South Korea | Filing, Examination, Granting | 2502 | |
| USA | Filing, Examination, Granting | 6090 |
Total:
33,834
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to the field of medicines. Specifically, the present invention relates to a pyrimidopyrazole compound, and a pharmaceutical composition thereof and a use thereof. Specifically, the present invention relates to a compound of formula (I), or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite, pharmaceutically acceptable salt or prodrug of the compound represented by formula (I), wherein each variable has the meaning as described in the present invention. The compound and the pharmaceutical composition thereof involved in the present invention, as TYK2 inhibitors, can be used in preparation of medicines for preventing or treating TYK2-related diseases.[French]
La présente invention relève du domaine des médicaments. Plus particulièrement, la présente invention concerne un composé de pyrimidopyrazole, une composition pharmaceutique de celui-ci et une utilisation associée. Plus particulièrement, la présente invention concerne un composé de formule (I) ou un stéréoisomère, un tautomère, un oxyde d'azote, un solvate, un métabolite, un sel pharmaceutiquement acceptable ou un promédicament du composé représenté par la formule (I), chaque variable présentant la signification telle que décrite dans la présente invention. Le composé et la composition pharmaceutique de celui-ci impliqués dans la présente invention, en tant qu'inhibiteurs de TYK2, peuvent être utilisés dans la préparation de médicaments pour la prévention ou le traitement de maladies associées à TYK2.[Chinese]
本发明属于药物领域，具体地，本发明涉及一种嘧啶并吡唑类化合物、其药物组合物及其用途。具体地，本发明涉及式(I)化合物，或式(I)所示化合物的立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐或前药，其中各变量具有本发明所述的含义。本发明涉及的化合物和其药物组合物作为TYK2抑制剂可用于制备用于预防或治疗TYK2相关疾病的药物。